71.51
price up icon0.53%   0.38
after-market After Hours: 50.00 -21.51 -30.08%
loading
Exact Sciences Corp stock is traded at $71.51, with a volume of 3.69M. It is up +0.53% in the last 24 hours and up +4.61% over the past month. Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$71.13
Open:
$70.56
24h Volume:
3.69M
Relative Volume:
1.80
Market Cap:
$13.21B
Revenue:
$2.53B
Net Income/Loss:
$-240.23M
P/E Ratio:
-45.10
EPS:
-1.5857
Net Cash Flow:
$-20.46M
1W Performance:
+2.69%
1M Performance:
+4.61%
6M Performance:
+15.21%
1Y Performance:
+6.70%
1-Day Range:
Value
$70.23
$72.83
1-Week Range:
Value
$67.57
$72.83
52-Week Range:
Value
$40.62
$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name
Name
Exact Sciences Corp
Name
Phone
608-284-5700
Name
Address
5505 ENDEAVOR LANE, MADISON, WI
Name
Employee
6,600
Name
Twitter
@exactsciences
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
EXAS's Discussions on Twitter

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-28-24 Initiated Wells Fargo Overweight
Jun-27-24 Initiated Scotiabank Sector Outperform
Jun-03-24 Resumed Jefferies Buy
Jan-02-24 Upgrade The Benchmark Company Hold → Buy
Dec-14-23 Initiated Guggenheim Buy
Dec-13-23 Initiated Wolfe Research Outperform
Oct-10-23 Upgrade Piper Sandler Neutral → Overweight
Sep-28-23 Initiated Bernstein Outperform
Aug-02-23 Downgrade The Benchmark Company Buy → Hold
May-10-23 Upgrade Craig Hallum Hold → Buy
May-05-23 Initiated UBS Neutral
Mar-09-23 Upgrade Citigroup Neutral → Buy
Feb-10-23 Downgrade Credit Suisse Outperform → Neutral
Jan-18-23 Downgrade Raymond James Outperform → Mkt Perform
Oct-19-22 Downgrade Craig Hallum Buy → Hold
Aug-25-22 Initiated Credit Suisse Outperform
Jun-03-22 Initiated Piper Sandler Neutral
Nov-03-21 Downgrade Raymond James Strong Buy → Outperform
Jul-29-21 Reiterated BTIG Research Buy
Jul-29-21 Reiterated Canaccord Genuity Buy
Jul-29-21 Reiterated Oppenheimer Outperform
Jul-29-21 Reiterated Stifel Buy
Jun-15-21 Initiated Raymond James Strong Buy
Jun-03-21 Initiated Goldman Buy
May-25-21 Initiated Wells Fargo Equal Weight
Jan-28-21 Initiated Truist Buy
Oct-29-20 Downgrade UBS Buy → Neutral
Oct-28-20 Downgrade Citigroup Buy → Neutral
Oct-08-20 Resumed BTIG Research Buy
Apr-02-20 Initiated Evercore ISI Outperform
Jan-10-20 Resumed BTIG Research Buy
Jan-07-20 Initiated Citigroup Buy
Dec-13-19 Initiated Dougherty & Company Buy
Nov-15-19 Initiated Stifel Buy
Oct-17-19 Reiterated BofA/Merrill Buy
Oct-01-19 Resumed Craig Hallum Buy
Sep-26-19 Initiated Oppenheimer Outperform
Feb-26-19 Upgrade Goldman Neutral → Buy
Oct-09-18 Initiated UBS Buy
Sep-05-18 Resumed The Benchmark Company Hold
Aug-13-18 Reiterated Canaccord Genuity Buy
Apr-03-18 Upgrade BTIG Research Neutral → Buy
Jan-29-18 Initiated Goldman Neutral
Jan-08-18 Reiterated The Benchmark Company Buy
Nov-13-17 Downgrade Robert W. Baird Outperform → Neutral
Nov-01-17 Downgrade BTIG Research Buy → Neutral
View All

Exact Sciences Corp Stock (EXAS) Latest News

pulisher
05:28 AM

Exact Sciences: Q3 Earnings Snapshot - San Antonio Express-News

05:28 AM
pulisher
05:07 AM

After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology - Investing.com

05:07 AM
pulisher
05:04 AM

Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates - Benzinga

05:04 AM
pulisher
04:41 AM

Exact Sciences Corp Q3 2024 Earnings: Revenue at $709M, EPS at -$0.21, Misses Estimates - GuruFocus.com

04:41 AM
pulisher
04:18 AM

Exact Sciences shares plummet on weak results, lowered guidance By Investing.com - Investing.com UK

04:18 AM
pulisher
04:05 AM

Exact Sciences Announces Third-Quarter 2024 Results - StockTitan

04:05 AM
pulisher
04:09 AM

New York State Common Retirement Fund Has $20.19 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

04:09 AM
pulisher
Nov 04, 2024

3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Exact Sciences Corp (EXAS) Stock Price Up 2.99% on Nov 4 - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Exact Sciences to Participate in November Investor Conference - Marketscreener.com

Nov 04, 2024
pulisher
Oct 29, 2024

Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Oct 29, 2024
pulisher
Oct 27, 2024

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement - Business Wire

Oct 27, 2024
pulisher
Oct 27, 2024

8,360 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Sequoia Financial Advisors LLC - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 25, 2024
pulisher
Oct 22, 2024

Will Screening Sales Drive Exact Sciences' Q3 Earnings? - Yahoo Finance

Oct 22, 2024
pulisher
Oct 21, 2024

Exact Sciences Corp (EXAS) Shares Gap Down to $69.69 on Oct 21 - GuruFocus.com

Oct 21, 2024
pulisher
Oct 19, 2024

Can This Beaten-Down Cathie Wood Stock Bounce Back? - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Friedenthal Financial Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 19, 2024
pulisher
Oct 17, 2024

Exact Sciences Cor (EXAS-Q) QuotePress Release - The Globe and Mail

Oct 17, 2024
pulisher
Oct 16, 2024

Exact Sciences Corporation (EXAS) Bounced Back in Q3 - Yahoo Finance

Oct 16, 2024
pulisher
Oct 10, 2024

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

Artemis Investment Management LLP Invests $7.27 Million in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Exact Sciences EVP sells shares worth over $65k - Investing.com India

Oct 10, 2024
pulisher
Oct 09, 2024

Exact Sciences EVP sells shares worth over $65k By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Str - GuruFocus.com

Oct 09, 2024
pulisher
Oct 09, 2024

Handelsbanken Fonder AB Acquires 9,400 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Exact Sciences Schedules Third Quarter 2024 Earnings Call - BioSpace

Oct 08, 2024
pulisher
Oct 07, 2024

Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish By Investing.com - Investing.com Australia

Oct 07, 2024
pulisher
Oct 07, 2024

FMR LLC Bolsters Stake in Exact Sciences Corp - GuruFocus.com

Oct 07, 2024
pulisher
Oct 07, 2024

Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

FDA greenlights Exact Science’s newest home colorectal cancer test - Medical Device Network

Oct 07, 2024
pulisher
Oct 07, 2024

Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test - Yahoo Finance

Oct 07, 2024
pulisher
Oct 05, 2024

Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio - Insider Monkey

Oct 05, 2024
pulisher
Oct 05, 2024

10 Buzzing AI Health Stocks - Insider Monkey

Oct 05, 2024
pulisher
Oct 04, 2024

FDA approves Exact Sciences' advanced CRC screening test By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

FDA approves Exact Sciences' advanced CRC screening test - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Exact Sciences shares hold as FDA approves new Cologuard test - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

FDA greenlights Exact Sciences’ Cologuard Plus - BioWorld Online

Oct 04, 2024
pulisher
Oct 04, 2024

Exact Sciences shares hold as FDA approves new Cologuard test By Investing.com - Investing.com Canada

Oct 04, 2024
pulisher
Oct 04, 2024

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test - Yahoo Finance

Oct 04, 2024
pulisher
Oct 04, 2024

Is EXAS Stock a Smart Addition to Your Portfolio Right Now? - Yahoo Finance

Oct 04, 2024
pulisher
Oct 04, 2024

Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test - StreetInsider.com

Oct 04, 2024
pulisher
Oct 04, 2024

FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening - The Bakersfield Californian

Oct 04, 2024
pulisher
Oct 04, 2024

Curbstone Financial Management Corp Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Oct 04, 2024

Exact Sciences Corp Stock (EXAS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$226.42
price up icon 3.48%
diagnostics_research LH
$229.11
price up icon 0.85%
diagnostics_research WAT
$387.17
price down icon 0.04%
$154.96
price up icon 0.96%
diagnostics_research MTD
$1,385.79
price up icon 1.60%
$415.98
price up icon 0.35%
Cap:     |  Volume (24h):